Noopept is a potent receptor site modulator and nootropic. Studies indicate its ability to increase memory and attention span, reduce worry and improve mood, and exhibit neuroprotective qualities.

Scientific Name:
N-phenylacetyl-L-prolylglycine ethyl ester


  • Racetam like properties (NMDA receptor modulator) and Ampakine like properties (AMPA glutamate receptor modulator)[1]
  • In the vicinity of 1,000 times the potency of piracetam[2]
  • Upregulates neurotrophin factors NGF and BDNF involved in neurogenesis and long term memory[3]
  • Acetylcholine and glutamate sensitizing effect[4,5]
  • Modulates EEG patterns in ways considered positive for calm alertness[1]
  • Neuroprotective effects from oxidative stress and glutamate excitotoxicity[6]
  • Anxiolytic effect – may be due to hippocampal regulation[7]
  • Cycloprolylglycine precursor – an endogenous anxiolytic neuropeptide[8]

[1] Vorobyov V, et al (2011). Effects of nootropics on the EEG in conscious rats and their modification by glutamatergic inhibitors. Brain Res Bull, 85(3-4):123-32. doi: 10.1016/j.brainresbull.2011.02.011
[2] Solntseva EI et al (1997). The effects of piracetam and its novel peptide analogue GVS-111 on neuronal voltage-gated calcium and potassium channels. Gen Pharmacol, 29(1):85-9. doi: 10.1016/S0306-3623(96)00529-0
[3] Ostrovskaya RU et al (2008). Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med, 146(3):334-7. doi: 10.1007/s10517-008-0297
[4] Firstova IuIu, et al (2011). Studying specific effects of nootropic drugs on glutamate receptors in the rat brain. Eksp Klin Farmakol, 74(1):6-10. PMID: 21476267
[5] Ostrovskaia RU, et al (2001). Behavioral and electrophysiological analysis of the choline-positive effect of nootropic dipeptide acylproline (GVS-111). Eksp Klin Farmakol, 64(2):11-4. PMID: 11548439
[6] Andreeva NA, et al (2000). Neuroprotective properties of nootropic dipeptide GVS-111 in in vitro oxygen-glucose deprivation, glutamate toxicity and oxidative stress. Bull Exp Biol Med, 130(10):969-72. doi: 10.1023/2FA.3A1002828707337
[7] Kondratenko RV, et al (2010). Novel nootropic dipeptide Noopept increases inhibitory synaptic transmission in CA1 pyramidal cells. Neurosci Lett, 476(2):70-3. doi: 10.1016/j.neulet.2010.04.005
[8] Gudasheva TA et al (1997). The major metabolite of dipeptide piracetam analogue GVS-111 in rat brain and its similarity to endogenous neuropeptide cyclo-L-prolylglycine. Eur J Drug Metab Pharmacokinet, 22(3):245-52. doi: 10.1007/2FBF03189814